A single base pair change in codon 6 of the ␤-globin gene causes sickle cell anemia in individuals who are homozygous for the mutation (1) . Sickle hemoglobin [HbS (␣ 2 ␤ S 2 )] undergoes polymerization upon deoxygenation, thereby distorting erythrocytes into a variety of sickled shapes, damaging the erythrocyte membrane, and ultimately causing anemia, ischemia, infarction, and progressive organ dysfunction. Despite the impressive body of knowledge that has accumulated (2), many aspects of sickle cell disease are still poorly understood and treatment options remain limited. Because of the inhibitory effects of mouse ␣-and ␤-globin on sickling, transgenic mice expressing various sickle hemoglobins (HbS, HbSAD, HbS-Antilles) develop almost none of the clinical manifestations of sickle cell disease (3) . Some sickle cell disease pathology has been reported in transgenic mice bred to produce higher concentrations of the "supersickling" hemoglobins (HbSAD and HbS-Antilles) (4); however, these animals still lack important features that are commonly found in humans with sickle cell disease (5) . To overcome these limitations, we have created mice that no longer express mouse ␣-and ␤-globin; instead, they express exclusively human ␣-and ␤ S -globin. Three fragments of human DNA were coinjected into fertilized mouse eggs to generate transgenic founders expressing human ␣-and ␤ S -globin (6). Because ␥-globin has antisickling properties, we included the G ␥-and A ␥-globin genes to decrease the likelihood that erythrocytes would sickle during gestation and cause fetal death. In the particular transgenic line that was generated [Tg(HuminiLCR␣1
G ␥-and A ␥-globin are expressed during the embryonic and fetal stages of development and not in adult mice (Fig. 1A) (Fig. 1B) compared with newborn humans, it is likely that these deaths are caused by the sickling of erythrocytes during the critical period just after birth when the lungs must begin the task of supplying oxygen. Sickle cell mice that survived this early critical period were able to reach adulthood (many are now more than 7 months old) with normal appearance, activity, and fertility (11). Erythrocytes in adult sickle cell mice contain exclusively human ␣-and ␤ S -globin (Fig. 1B) . There is an excess of ␣-globin chain synthesis (␣/␤ S , 1.26 Ϯ 0.02; (12), which indicates that these sickle cell mice are slightly ␤-thalassemic.
Common findings in humans with sickle cell anemia include irreversibly sickled cells (ISCs), anemia, and increased rigidity of erythrocytes. Sickle cell mice are anemic, with average hematocrits only 65% of normal, and have markedly elevated reticulocyte counts (Table 1) . ISCs, indicative of repeated cycles of in vivo sickling and unsickling, were observed at a frequency of 5 to 10% in oxygenated sickle cell mouse blood ( Fig. 2A) . Upon deoxygenation in vitro (13) , classically sickled cells formed at high frequency. Erythrocytes from sickle cell mice have significantly decreased osmotic fragility and increased dynamic rigidity (Fig. 2B ) as measured by osmotic gradient ektacytometry (14) . The various hematologic and erythrocytic perturbations that exist in these sickle cell mice closely parallel those observed in humans with sickle cell anemia (2) .
The final and most serious manifestation of sickle cell disease in humans is damage to multiple organs. In sickle cell mice, kidney and heart weights increased 2-fold, and spleen weight increased 13-fold compared with wild-type controls (15) . Long-term increases in cardiac output and splenic erythropoiesis, both in response to the chronic anemia that exists in these mice, are likely to be responsible for the observed increases in heart and spleen weights. Histologic analysis (16) revealed tissue damage in multiple organs ( Fig. 3) : kidney (fibrosis, atrophy, infarcts, cysts; Fig. 3B ), lung (vascular congestion; Fig. 3D ), liver (multifocal ischemic infarcts; Fig. 3 , E and F), and spleen (congested sinusoidal channels). Increased iron deposits were found in liver (Kupffer cells) and kidney (tubular epithelium). The extent and nature of the congestion, atrophy, fibrosis, and infarct found in organs of these sickle cell mice is very similar to what has been reported in humans with sickle cell disease (17) .
We have extensively reengineered the murine globin system to create mice that express exclusively human sickle hemoglobin and that faithfully recapitulate the major genetic, hematologic, and histopathologic features of humans with sick- le cell anemia. In contrast to the limited studies that can be performed in humans, these animals provide an opportunity for rapidly exploring an expanded range of inquiry in an in vivo setting. As such, these sickle cell mice are likely to play an important role in furthering our understanding of the pathophysiology of sickle cell disease and in developing improved therapies for treating the more than 100,000 individuals born each year with this genetic disease.
Note added in proof:
With a similar approach, we have also created mice that express exclusively normal human hemoglobin (HbA). One possible explanation for this is the presence of segregating "survival" alleles in the mixed genetic background (FVB/N, 129, DBA/2, C57BL/6, Black Swiss) of the breeding population. These alleles would be inherited at a higher frequency from sickle cell males than from non-sickle cell males. Another possible explanation involves the presence of fewer healthy non-sickle cell newborns in litters from sickle cell males. This might allow sickle cell newborns to compete more effectively for maternal attention and enable them to survive more readily. The following animal husbandry practices may influence the survival of sickle cell mice: Micro-Barrier Systems cages
TECHNICAL COMMENTS

Government Funding of Research and Development
In a Policy Forum, Robert M. May (1) uses bibliometric data from an Australian benchmarking study (2) to show that the United Kingdom had the most cost-effective science base among G7 countries (3), as measured by citations attracted per million pounds (per £million) spent. In doing so, May, who is the Chief Scientist of the United Kingdom, has established a baseline that raises the profile of quantitative studies in science policy and against which investigators can measure future performance. Part of May's analysis rests on the assumption that there is a relationship between financial investment in research and development (R&D) and scientific impact, as measured by citations to papers published in the peer reviewed serial literature. Although it is reasonable to assume that there is such a relationship, we have two main concerns with May's analysis. First, he does not allow for a time lag between expenditure on R&D and the evaluation of a country's scientific impact. By taking this into account, we demonstrate that United Kingdom (U.K.) science is not the most costeffective of the G7. Second, we argue that it is incorrect to relate the citation performance of the national science system only to government expenditure, because private and overseas funders have made an increasingly large contribution to public domain U.K. science in recent years.
May estimates (1) return on investment for a single year (1991) based on the yearly average number of citations over the period 1981-94 (4). However, expenditure in 1991 will have little effect on citations before about 1997 because there is commonly a 4-year lag before papers emerge from the funded research and at least a further 2-year period before the citation peak is reached. The preferred analysis would be to compare expenditure figures for each year with citations achieved (say, 4 to 6 years later) and to track this over time. Because May takes SCIENCE ⅐ VOL. 278 ⅐ 31 OCTOBER 1997 ⅐ www.sciencemag.org
